Features Partner Sites Information LinkXpress
Sign In
Demo Company

Sartorius Stedim Biotech Extends Portfolio with Majority Stake in AllPure Technologies

By BiotechDaily International staff writers
Posted on 04 May 2014
Print article
Sartorius Stedim Biotech (SSB; Aubagne, France) has signed a contract to acquire the majority stake in the privately owned start-up AllPure Technologies LLC (New Oxford, PA, USA). AllPure Technologies designs, manufactures, and markets innovative aseptic sampling and tube sealing systems for biopharmaceutical and pharmaceutical drug developers and manufacturers; it has been on the market for 4 years, and in 2013 earned revenue of around USD 3 million, with 25 employees. SSB, dedicated to a philosophy of “turning science into solutions,” is a leading global R&D company and provider of cutting-edge equipment, products, and services for the pharmaceutical and biotech industries; it employs approx. 3,300 people, and in 2013 earned sales revenue of EUR 588.4 million.

The takeover extends SSB's portfolio for single-use bioprocessing as AllPure specializes in innovative single-use components for biopharmaceutical applications, such as aseptic sampling techniques. AllPure has launched advanced products to improve operating efficiencies, process reliability, and operator safety. Supported by numerous patent-pending technologies, its products provide quick, reliable, and safe solutions to the shortcomings of current aseptic sampling techniques. AllPure operates in a state-of-the-art facility, and complies with applicable cGMP guidelines.

“AllPure further completes our portfolio with innovative products that help our customers develop and manufacture their pharmaceutical drugs safer and more efficiently. I am really looking forward to working with the AllPure team and to all that we can accomplish together,” said Reinhard Vogt, member of SSB’s Executive Board. "We are excited to leverage Sartorius Stedim’s impressive R&D capabilities so that we can accelerate the launch of new products from AllPure. And SSB’s global reach and industry relationships grant access to considerably more customers, especially in Europe and Asia, which have tremendous potential for AllPure’s products,” said Michael Zumbrum, President of AllPure. SSB and AllPure agreed not to disclose further details of the purchase agreement.

Related Links:

Sartorius Stedim Biotech 
AllPure Technologies 

Print article



view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

How Blocking TROY Signaling Slows Brain Cancer Growth

Cancer researchers have found how the low molecular weight drug propentofylline (PPF) slows the growth of the aggressive brain tumor glioblastoma multiforme (GBM). This form of brain cancer is the most... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.